Neuroendocrine Tumors: Germline Genetics and Hereditary Syndromes
- PMID: 39821711
- DOI: 10.1007/s11864-024-01288-z
Neuroendocrine Tumors: Germline Genetics and Hereditary Syndromes
Abstract
The vast majority of neuroendocrine 'neoplasms (NENs) are sporadic, although recent evidence has indicated that a subset of these cancers may also originate as a result of genetic germline mutations. To date, 10% of these cancers can be linked to an inherited genetic syndrome. Genetic diagnosis is crucial for patients with a suspected hereditary NEN syndrome, as it recognizes patients carrying germline mutations and allows for personalized clinical follow-up, considering the higher risk of developing other tumours. The potential for early genetic detection has significant implications for the treatment of patients with hereditary NEN syndrome, as it may facilitate the delivery of precision therapy that differs from that typically provided to other patients. Thus, the integration of genotypic and phenotypic diagnostic methods help clinicians to provide more informed treatment and to extend appropriate prevention to family members.
Keywords: Germline mutations; Hereditary syndromes; Neuroendocrine tumors.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors. Competing Interests: The authors declare no competing interests.
Similar articles
-
Update on Cancer Predisposition Syndromes and Surveillance Guidelines for Childhood Brain Tumors.Clin Cancer Res. 2024 Jun 3;30(11):2342-2350. doi: 10.1158/1078-0432.CCR-23-4033. Clin Cancer Res. 2024. PMID: 38573059 Free PMC article. Review.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
Preferences for Genetic Testing to Predict the Risk of Developing Hereditary Cancer: A Systematic Review of Discrete Choice Experiments.Med Decis Making. 2024 Apr;44(3):252-268. doi: 10.1177/0272989X241227425. Epub 2024 Feb 7. Med Decis Making. 2024. PMID: 38323553 Free PMC article.
-
Hemophilia B.2000 Oct 2 [updated 2025 Aug 7]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2000 Oct 2 [updated 2025 Aug 7]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301668 Free Books & Documents. Review.
-
Short-Term Memory Impairment.2024 Jun 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Jun 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31424720 Free Books & Documents.
Cited by
-
An Analysis of Primary Hyperparathyroidism in Individuals Diagnosed with Multiple Endocrine Neoplasia Type 2.Diseases. 2025 Mar 27;13(4):98. doi: 10.3390/diseases13040098. Diseases. 2025. PMID: 40277809 Free PMC article. Review.
References
References and Recommended Reading
-
- Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J Clin. 2018;68(6):471–87. https://doi.org/10.3322/caac.21493 . - DOI - PubMed
-
- Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3(10):1335–42. https://doi.org/10.1001/jamaoncol.2017.0589 . - DOI - PubMed - PMC
-
- Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022;33(1):115–54. https://doi.org/10.1007/s12022-022-09708-2 . - DOI - PubMed
-
- Gieldon L, Masjkur JR, Richter S, et al. Next-generation panel sequencing identifies NF1 germline mutations in three patients with pheochromocytoma but no clinical diagnosis of neurofibromatosis type 1. Eur J Endocrinol. 2018;178(2):K1–9. https://doi.org/10.1530/EJE-17-0714 . - DOI - PubMed
-
- Chandrasekharappa SC, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (New York, NY). 1997;276(5311):404–7. https://doi.org/10.1126/science.276.5311.404 . - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources